Variability in the Clinical Effects of the Omega-3 Polyunsaturated Fatty Acids DHA and EPA in Cardiovascular...

Area of Science:

• Cardiovascular research
• Nutritional science
• Molecular biology

Background:

• Cardiovascular disease (CVD), including heart attack and stroke, is a leading global cause of death.
• Atherosclerosis, the main cause of CVD, can be managed with lifestyle and pharmacological interventions, such as n-3 polyunsaturated fatty acid (PUFA) supplementation.
• n-3 PUFAs, notably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), show potential in reducing atherosclerosis by targeting risk factors like high triglycerides and inflammation.

Purpose of the Study:

• To review the conflicting findings of clinical studies on n-3 PUFAs for atherosclerosis.
• To discuss factors contributing to inconsistencies, including study design and the distinct molecular effects of EPA and DHA.
• To propose improvements for clinical and experimental study designs and supplement optimization.

Main Methods:

• Literature review of clinical studies on n-3 PUFAs and atherosclerosis.
• Analysis of molecular mechanisms of EPA and DHA in cellular function.
• Evaluation of factors influencing study outcomes, such as study design and patient variability.

Main Results:

• Conflicting results from large clinical trials on n-3 PUFAs have created public and professional confusion.
• n-3 PUFAs influence atherosclerosis through mechanisms including altering cell membrane composition, regulating transcription factors, and inducing epigenetic changes.
• EPA and DHA exert both shared and distinct molecular effects on cellular function.

Conclusions:

• Inconsistencies in n-3 PUFA research stem from study design flaws and the differential effects of EPA and DHA.
• Optimizing future study designs and supplement composition is crucial for effective n-3 PUFA use.
• Developing biomarkers to predict individual responses to n-3 PUFAs could enable personalized therapeutic strategies for atherosclerosis.